SM
ZVRA icon

Sabby Management’s Zevra Therapeutics ZVRA Stock Holding History

Sabby Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,735
Closed -$2.22M – 203
2021
Q2 		$2.22M Sell
1,735
-2,458
-59% -$26.4K 0.31% 49
2021
Q1 		$3.86M Buy
+4,193
New +$36.6K 0.75% 23

Other funds holding ZVRA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Sabby Management's ZVRA Position: Q1 2023 in Review

Sabby Management sold out of Zevra Therapeutics (ZVRA) in Q1 2023, closing a stake of 70,000 shares — an estimated $321K sold.

Sabby Management first reported a position in ZVRA in Q2 2021 and held it in 7 quarters. The position peaked at $2.21M in Q2 2021. 60 funds tracked by Wall St. Rank hold ZVRA as of Q1 2023.

  • Sabby Management reported no remaining Zevra Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Sabby Management sold 70,000 Zevra Therapeutics shares in Q1 2023, an estimated $321K.
  • Sabby Management first reported a position in Zevra Therapeutics in Q2 2021 and held it in 7 quarters.
  • Sabby Management's Zevra Therapeutics position peaked at $2.21M in Q2 2021.
  • 60 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2023.

Based on Sabby Management's 13F filing for Q1 2023, filed 15 May 2023.